January 17, 2025 07:00 AM ESTUpdated 06:10 PM

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze “late last year,” the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Roche no longer wants to be where ‘DNA sequencing goes to die’

Merck KGaA tees up changes to leadership team; Ex-CVS Health CEO joins Thermo Fisher’s board

Trump’s HHS defends drug price negotiations in Novartis suit

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

Copy Chief

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down